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he following review of current pharmacological
treatments for nicotine, alcohol, cocaine, and opioid
dependence addresses pharmacotherapies aimed at two
stages of treatment: (i) acute withdrawal or the initial
attainment of abstinence and (ii) chronic maintenance
or prevention of relapse. Maintenance pharmacothera-
pies act as either blocking or substitution agents to atten-
uate protracted withdrawal symptoms.Detoxification is
required prior to administration of a blocking agent, in
order to prevent withdrawal from an abused agent. For
example, naltrexone, a competitive opioid antagonist,
completely blocks the subjective euphoria and produc-
tion of physiological dependence of heroin use.
Substitution agents will not precipitate withdrawal when
given to drug-dependent patients, and instead act to
reduce withdrawal symptoms and the desire for more
drugs.Substitution agents may also produce cross-toler-
ance to other drugs from the same pharmacological
class. Methadone is one example of an agent that is
effective in reducing illicit opioid use by producing cross-
tolerance to heroin.The need for these pharmacothera-
pies is highlighted by the sharp increase in the rate of
even the relatively uncommon abuse of opiates; 12.4%
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Addiction to substances continues to be a significant pub-
lic health concern in the United States. The following
review of current pharmacological treatments discusses a
range of substances: nicotine, alcohol, cocaine, and opi-
oids. The goal is to provide an overview of currently avail-
able and new pharmacological treatments for substance
use disorders, while also addressing the pharmacothera-
peutic challenges remaining. The significant advances in
pharmacotherapy have had limited utilization, however.
For example, naltrexone for alcoholism is infrequently pre-
scribed, buprenorphine for opiates still has relatively few
qualified prescribers, and stimulants have no Food and
Drug Administration-approved pharmacotherapy. These
pharmacotherapies are needed, with the rate of even the
relatively uncommon abuse of opiates now rising sharply.   
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In 2005 approximately 20.9% of US adults were cigarette
smokers.
1 New medications and counseling have helped
many smokers quit,but the majority of those who try to
quit are still unsuccessful.
3-5 Pharmacotherapies range
from nicotine replacement therapy to antidepressants for
the relief of acute withdrawal symptoms and relapse pre-
vention.
Nicotine replacement therapies
Nicotine replacement therapies (NRT) are designed to
replace nicotine obtained through smoking in order to
attenuate tobacco withdrawal symptoms and improve
smoking cessation outcomes. There are currently five
Food and Drug Administration (FDA)-approved NRT
products, which include: the transdermal patch, gum,
lozenge, inhaler, and nasal spray. These products are
available over-the-counter or by prescription.They can
be given alone or taken in conjunction with antidepres-
sants like bupropion in order to alleviate acute with-
drawal symptoms and sustain abstinence.A small dose of
nicotine in these products allows the patient to reduce
nicotine withdrawal symptoms after the patient has
stopped smoking.Patients are often counseled to quit,
provided options for treatment,and helped to establish
a quit date.On the quit date the NRT is started and other
forms of tobacco use are stopped.
6 Choice of specific
NRT typically depends on the patient’s preference,the
side-effect profile,and the route of administration.
7
The nicotine transdermal patch is available in 16- or 24-
hour delivery systems.Recommended duration of use is
6 to 12 weeks,with a tapering of the patch dose over that
period.Patients usually start with a high-dose patch (21
or 22 mg);however,an intermediate-dose patch (11 or 14
mg) is available for those who smoke fewer than 15 cig-
arettes per day.
5Though patients usually develop toler-
ance to common side effects,they may experience insom-
nia, nausea, and vivid dreams. Skin irritation can also
occur,and is usually alleviated with rotation of the patch
placement site.
8-11The nicotine patch can also be utilized
in combination with other NRT,such as the gum,which
increases its efficacy in treatment-resistant cases.
12
Nicotine polacrilex gum and lozenges are available over-
the-counter as aids in smoking cessation in 2 and 4 mg
doses of nicotine. The 4-mg dose is recommended for
heavy smokers (>25 cigarettes per day).
8,13,14The recom-
mended dosage of nicotine gum is to use one piece every
1 to 2 hours.
6The nicotine lozenge should be sucked on
rather than chewed. The lozenge delivers about 25%
more nicotine than the gum, since some nicotine is
retained in the gum and the lozenge is dissolved com-
pletely.
15The dose can be tapered over 6 to 12 weeks by
either decreasing the gum or lozenge dose from 4 mg to
2 mg or by increasing the time between doses,
6 with peak
concentrations of nicotine absorbed through the buccal
mucosa achieved in 15 to 30 minutes.
16,17 Nicotine absorp-
tion can be blunted with use of acidic beverages;there-
fore,coffee,juices,and soda should be avoided immedi-
ately before or during NRT use.
18 Side effects of the gum
may include jaw soreness or difficulty chewing.
13,19 The
lozenge offers an alternative to gum but also may elicit
side effects such as nausea,heartburn,and mild throat or
mouth irritation.
13,19
The nicotine inhaler and nicotine nasal spray are avail-
able by prescription only and provide faster delivery of
nicotine than gum or lozenge;4 to 15 minutes for nasal
spray,15 minutes for the inhaler.
20The spray is adminis-
tered to each nostril every 1 to 2 hours with a range of 8
to 40 doses per day.
21The usual recommended dose is 1
mg per administration over 8 weeks.Gradual taper is rec-
ommended between weeks 9 and 14.
21 Side effects of the
nasal spray may include nasal and throat irritation,sneez-
ing,coughing,and watery eyes.
22-24The nicotine inhaler
administers nicotine via cartridges placed in cigarette-like
plastic rods which produce a nicotine vapor (0.013
mg/puff) when inhaled.
25,26 The nicotine is absorbed
through the buccal mucosa and following inhalation.The
recommended dose is 6 to 16 cartridges daily,with use for
approximately 12 weeks.
6 Each cartridge contains 10 mg
of nicotine and delivers a maximum of 4 mg of nicotine,
and provides approximately 20 minutes of active puffing.
Peak plasma nicotine concentrations are typically
achieved within 15 minutes.
20Throat irritation or cough-
ing can occur in up to 50% of inhaler users.
26,27 Because
of the rapid delivery of the spray and inhaler, there is
some potential for abuse liability after quitting smoking,
leading to continued use >6 months.
28-31
Patients who utilize nicotine replacement therapy improve
their likelihood of quitting by 1.5 to 2 times.
6,32 Long-term
efficacy of NRT on smoking cessation may actually be
modest,however (5% to 10% above placebo).
33 Most tri-
als assess the effect of smoking reduction at 1 year or less,
and the effect is attenuated by about 12% after 12 months




The observed relationship between nicotine dependence
and mood disorders such as depression supports the use
of antidepressant medications as effective pharma-
cotherapies for cigarette smoking cessation.
34 Sustained-
release bupropion,an atypical antidepressant agent,has
been the most commonly used medication for the phar-
macotherapy of smoking cessation,improving quit rates
in short- and long-term follow-up.Bupropion blockade
of norepinephrine and dopamine uptake may attenuate
nicotine withdrawal symptoms.In addition,bupropion
also blocks the nicotinic acetylcholine receptor, thus
offering a potential reduction in the reinforcing effects
of nicotine.
35,36 Patients start treatment at the recom-
mended 150 mg/day 7 days prior to their target quit date,
since steady-state plasma levels are achieved within 1
week of initiation. Dosing is then increased to 300
mg/day after 3 to 4 days.
6 Bupropion can also be used in
combination with NRT.Two large,multicenter clinical tri-
als demonstrated the efficacy of bupropion for the treat-
ment of nicotine dependence,and it is recommended as
a first-line treatment for smoking cessation.
21 Bupropion
alone (30%),or in combination with the nicotine patch
(35%),was demonstrated to be significantly more effec-
tive at 1-year follow-up than the nicotine patch alone
(16%) or placebo (16%).
37 For patients with a history of
depression,the bupropion dose is equivalent,allowing
for the pharmacological treatment of both disorders
simultaneously.
6 Side effects of bupropion primarily con-
sist of gastrointestinal symptoms,rash,headache,insom-
nia, and dry mouth.
38 As with other antidepressants,
bupropion lowers seizure threshold,so it should not be
used in patients with a history of seizure disorders.
6
Second-line pharmacotherapies for smoking cessation
include nortriptyline, clonidine, selegiline and, most
recently,varenicline.Nortriptyline,like bupropion,is an
antidepressant that shows promising effects for smoking
cessation.
39,40 It may also be useful in the treatment of
depressed cigarette smokers;however,its efficacy does
not appear to depend on comorbidity with a depressive
disorder.
6Though shown to be efficacious,nortriptyline
has significant side effects which limit its safety (eg,risk
of toxicity in overdose amounts).
6 Clonidine,an antihy-
pertensive agent,is an α-22-adrenergic receptor agonist
that decreases central sympathetic activity.It may be an
effective treatment option for those who have failed
other smoking cessation methods.Side effects from its
clinical use include sedation,dizziness,dry mouth,con-
stipation,and orthostatic hypotension.
41-43 Other agents
(eg selegiline and mecamylamine) have also been stud-
ied,but their efficacy for smoking cessation has not yet
been established.For example selegiline,a monoamine
oxidase-B (MAO-B) inhibitor for the treatment of
Parkinson’s disease may also be useful in reducing nico-
tine craving by decreasing dopamine metabolism.
44-45
Partial agonist
Varenicline,an α4β2 nicotinic acetylcholine receptor par-
tial agonist,is an efficacious treatment for smoking ces-
sation.Clinical trials indicate that this partial agonist can
reduce craving and withdrawal symptoms following ces-
sation or reduction of nicotine consumption.In addition
its partial antagonism can also reduce smoking satisfac-
tion through the occupation of the receptors and block-
ing the full agonist nicotine from binding.
46Varenicline,
administered 1 mg twice daily,has demonstrated superi-
ority to placebo and bupropion.
46, 47 It is generally safe
and well tolerated.Nausea and insomnia are commonly
reported adverse reactions to varenicline.
46,47
Nicotine vaccine
Currently,three nicotine vaccines have completed phase
I-II clinical trials;NicVAX,CYT002-NicOb,and TA-NIC.
In a phase II clinical trial,68 smokers were randomized to
receive one of 3 doses of a nicotine conjugate vaccine,
NicVax (50,100,or 200 µg) or placebo.The vaccine was
shown to be safe and well tolerated.In addition,vaccine
immunogenicity was dose-related (P<0.001) with the high-
est rate of 30-day abstinence occurring with 200 µg
(P<0.02).
48The NicQb vaccine was also shown to elicit sig-
nificant quantities of antinicotine antibodies,
49 and a sim-
ilar observation was made that subjects in the upper third
of antibody responses had almost two times the quit rate
of placebo (57% vs 31%).Subjects in the TA-NIC vaccine
trial were immunized with 4 doses over the first 8 weeks
and then given a booster dose at 32 weeks.All subjects
were encouraged to quit smoking after 12 weeks of the
trial,and at 12 months,the quit rate in the highest-dose
group significantly exceeded the control group (38% vs
8%).
50 Based on these studies suggesting that high anti-
body titers correlate with smoking cessation,evaluation of
nicotine conjugate vaccines are progressing and a phase
IIb/III trial was recently announced for NicQb.
51
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Alcohol dependence is a major cause of morbidity and
mortality in the United States and throughout the world.
Acute withdrawal from alcohol is a serious medical con-
dition which can precipitate adrenergic activation,
seizures,or delirium tremens,the last condition leading
to 15% mortality when untreated.
52 Many medications
have been evaluated for the treatment of alcohol depen-
dence in recent years,including those that interact with
dopaminergic, serotonergic, opioid, glutamate, and γ-
aminobutyric acid (GABA) systems.
Acute withdrawal
Benzodiazepine use is the standard approach to treating
withdrawal symptoms such as irritability,autonomic hyper-
activity,and seizures associated with alcohol detoxifica-
tion.Benzodiazepines act at GABA-A receptors to stim-
ulate GABA release and gradually detoxify the patient
from alcohol,thus avoiding associated withdrawal symp-
toms.
53The current standard approach to alcohol detoxifi-
cation uses tapering dosages of benzodiazepines such as
chlodiazepoxide, clonazepam, diazepam, oxazepam, or
lorazepam.
54,55
Anticonvulsants,including carbamazepine and valproate,
have also been studied for their efficacy in alcohol with-
drawal treatment.
6 Carbamazepine has been widely used
in alcohol withdrawal.Carbamazepine has demonstrated
its superiority to placebo in the speed of onset to relieve
alcohol withdrawal symptoms such as tremor,sweating,
palpitations,sleep disturbances,depression,anxiety,and
anorexia.
56 Furthermore,studies have also demonstrated
that higher success rates and reduction in withdrawal
symptoms in patients treated with carbamazepine than
with benzodiazepines.
57-59
Relapse prevention and maintenance
Disulfiram,acamprosate,oral naltrexone,and extended-
release injectable naltrexone have FDA approval for the
treatment of alcohol dependence.
Disulfiram is the first agent to be approved for treatment
of alcohol dependence and has been used for over 40
years.It acts as an alcohol-sensitizing agent,creating an
aversion to alcohol.Disulfiram is an irreversible inhibitor
of the enzymatic conversion of acetalaldehyde to acetic
acid.Accumulation of acetalaldehyde results in the disul-
firam-alcohol reaction:hypotension,flushing,nausea,and
vomiting.
60,61 Patients must be motivated to remain absti-
nent and comply with prescribed dosing;usual dosage is
250 mg/day.However,some patients may receive optimal
benefit from 125 to 500 mg/day.
6 Additional unpleasant
symptoms such as chest pain,seizures,hepatotoxicity,renal
failure, and even death have been reported in severe
cases.
6,62 Controlled trials of disulfiram versus placebo have
not demonstrated significant improvement over
placebo,
63,64 and meta-analyses have only shown slight
improvement in drinking.
65A large Veterans Cooperative
Study with over 600 subjects found,however,that disulfi-
ram may be effective in patients with no major comorbid
psychiatric disorder and who were motivated for absti-
nence.
64 More recently,an evaluation of subjects with cur-
rent depression on disulfiram reported lower craving over
time than subjects with depression on naltrexone.
66 The
utility of combining disulfiram with other therapeutic
interventions has also been examined.In a trial of disul-
firam and acamprosate,the number of abstinent days was
greater when utilizing a combination of disulfiram and
acamprosate than using either medication alone.
67
Naltrexone acts as an antagonist at the opioid receptors,
which are known to mediate the rewarding effects of alco-
hol and thus thought to reduce desire or craving of alcohol.
Studies have found that naltrexone is more effective than
placebo in promoting abstinence,reducing heavy drinking
days and decreasing relapse rates,
6,68-70 particularly when it
is combined with cognitive behavioral therapy.
71-73
Naltrexone has also shown greater efficacy when compared
with acamprosate.In a randomized controlled trial com-
paring the efficacy of acamprosate and naltrexone in the
treatment of alcohol dependence,significant increases in
time to first relapse was seen in those receiving naltrexone
in subjects with no depression and low dependency.
74
Furthermore, combined pharmacotherapy studies have
also demonstrated that naltrexone administered with
behavioral therapy can significantly reduce the risk of
heavy drinking.
75 Naltrexone is prescribed as 50 mg oral
administration,most commonly for 12 weeks,and can also
be given as a long-acting depot formulation every 4 weeks.
Acamprosate attenuates alcohol desire or craving by nor-
malizing the dysregulation of N-methyl-D-aspartate
(NMDA)-mediated glutaminergic excitation that occurs
in alcohol withdrawal and early abstinence.Acamprosate,
when given at 2 g administered three times daily, has
increased abstinence by 50% in over 3000 patients across
a dozen clinical trials.
76-78 Side effects such as diarrhea are
Pharmacological aspects
434generally well tolerated. A placebo-controlled trial
enrolled 272 patients and treated patients for 48 weeks.
Compared with placebo, acamprosate-treated alcohol-
dependent patients had twice the rate of sustained absti-
nence at 48 weeks (43% vs 21%),and this difference from
placebo was sustained at 96 weeks after starting the med-
ication (37% vs 17%).
78 Thus, this appears to be a very
effective approach to treating patients in order to main-
tain alcohol abstinence after detoxification.
Topiramate, an anticonvulsant medication, has been
shown to improve the drinking outcomes of alcohol-
dependent individuals vs placebo, but only in a single
study thus far,by Johnson et al.
79 In this topiramate study
the patients were actively drinking when started on med-
ication, rather than being first detoxified from alcohol
and being abstinent.The outcome was remarkable,with
an increase from no days abstinent at baseline to 44% of
days abstinent by week 12,compared with 18% of days
abstinent for the placebo group.In cases of dual depen-
dency on opiates and alcohol,topiramate may be useful
at a low dose in buprenorphine or methadone main-
tained,alcohol-abusing patients who do not need med-
ical detoxification for alcohol.
Serotonergic agents, including buspirone (a serotonin
[5HT]-1A agonist),
80 selective serotonin uptake inhibitors
(SSRIs),and the 5-HT3 antagonist ondansetron
81 have
been studied more extensively as treatments for alcohol
dependence.Fluoxetine or citalopram,two SSRIs,have
been effective in reducing alcohol consumption in some
studies,though results have been inconsistent.
82-89 Results
may be inconsistent due to heterogeneity in study popu-
lations.For example,Kranzler et al suggested that SSRIs
may be more effective in heavy drinkers or those with a
family history of alcoholism, as well as those with a
comorbid major depressive disorder.
Cocaine
Cocaine addiction affected approximately 2.4 million peo-
ple in the United States in 2005.
2 Behavioral interventions
are helpful in treating cocaine addiction, but currently
there are no approved medications to treat this disorder
despite over 60 medications having been investigated.
Dopaminergic agents
Directly acting dopaminergic agents such as bromocrip-
tine and pergolide have had limited efficacy,but indirect
mechanisms for increasing dopamine seem to be a
promising approach.
90,91 Disulfiram indirectly increases
dopamine by inhibiting dopamine-β-hydroxylase (DBH),
the enzyme that converts dopamine to norepinephrine.
In outpatient clinical trials,disulfiram (250 mg/day) has
been successful in reducing cocaine use with few associ-
ated adverse events,
92,93 with sustained results in reduc-
tion of cocaine and alcohol use at 1-year follow-up.
Findings have been replicated.
92 Disulfiram may be an
effective medication for reduction in cocaine use;how-
ever,it may not be suitable for treatment in all popula-
tions.
92,94,95 Nich et al reported that men responded to
disulfiram in reduction of cocaine use,whereas women
did not.
96 Further studies are needed to determine the
optimum dose and duration of treatment with this agent,
as well as to assess the efficacy of disulfiram related to
gender and comorbid conditions such as alcohol use or
opioid dependence.
Selegiline, a monoamine oxidase (MAO)-B inhibitor,
blocks the catabolic enzyme that breaks down dopamine
resulting in greater synaptic levels of dopamine. This
medication also exhibits amphetamine–like effects and
can enhance dopamine release and block dopamine
reuptake.
97A laboratory study of cocaine users showed
that short-term treatment with selegiline did not alter
physiological or subjective effects of cocaine.
98 In another
study however,cerebral metabolic effects of cocaine and
attenuated the cocaine “high”were altered by selegiline.
99
Antidepressants
Antidepressants are another class of medications also
used to treat cocaine dependence.Chronic stimulant use
causes presynaptic upregulation,and antidepressants are
thought to contribute the opposite effect by downregu-
lating synaptic catecholamine receptors.
100Although anti-
depressants have a relatively benign side-effect profile,
good patient compliance rates,and lack of abuse liabil-
ity,only desipramine,a tricyclic antidepressant,has shown
some efficacy in selected populations of cocaine
abusers.
6,100Though a meta-analysis of placebo-controlled
studies showed that desipiramine produced greater
cocaine abstinence than placebo,
101 other studies failed to
report positive findings with desipramine.
6,102 Secondary
analyses of studies with imipramine, desipramine, and
bupropion have suggested that depressed cocaine
abusers are more likely to show significant reductions in
cocaine abuse than nondepressed cocaine abusers.
103-105
Therapeutic options and challenges - Gardner and Kosten Dialogues in Clinical Neuroscience - Vol 9 . No.4 . 2007
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gested its efficacy in opioid-dependent patients,particu-
larly in combination with contingency management ther-
apies.
106,107 Early studies suggested some efficacy for
fluoxetine and bupropion, but this has not been con-
firmed in controlled trials.
6,108
GABA agonists
GABA agonists show promise in treatment for cocaine,
following initial studies.Baclofen,for example has shown
greater reduction in cocaine use compared with placebo
and may be more efficacious among individuals with
greater cocaine use.
109
Tiagibine,a GABA reuptake inhibitor,has also reduced
the reinforcing effects of cocaine by attenuating cocaine-
induced dopamine release.In a clinical trial investigating
the efficacy of tiagibine for cocaine use in opioid-depen-
dent patients maintained on methadone,tiagabine dose-
dependently attenuated cocaine use as measured with
self-reports and urine drug screening.
110,111 In a 10-week
double-blind,placebo controlled trial of treatment seek-
ing,cocaine-dependent,methadone-treated subjects,clin-
ical efficacy of gabapentin was compared with tiagabine
for reduction of cocaine use. Tiagabine significantly
reduced cocaine-taking behavior compared with placebo
or gabapentin-treated subjects.
111
Topiramate,another GABA-enhancing medication with
a primary therapeutic indication for epilepsy,has yielded
promising results for cocaine dependence as well.In a 14-
week,double-blind,placebo-controlled outpatient study,
subjects assigned to topiramate had more negative urine
cocaine results than placebo.
112 Results suggest potential
efficacy for GABAergic treatments for cocaine depen-
dence, but outcomes must be replicated in additional,
larger clinical trials.
Most recently,vigabatrin has shown efficacy in clinical
studies for cocaine abusers,and placebo-controlled mul-
tisite studies are under way examining it for cocaine
dependence.
113
Other treatment agents and approaches
In addition to the dopaminergic agents and antidepres-
sants,a number of miscellaneous agents,including aman-
tadine, carbamazepine, and buprenorphine, have been
examined for cocaine pharmacotherapy.Carbamazepine
failed to show therapeutic effects in three controlled
studies after an initial enthusiasm.
85,114,115 Buprenorphine
also has had more negative than positive findings sup-
porting its efficacy in treating cocaine-abusing opiate
addicts.
116-119 Studies of another agent,amantadine,have
reported mixed results.
120-123 In a trial of cocaine-depen-
dent men treated for 10 days with amantadine 100 mg
twice daily,urine toxicology screens were more likely to
be free of cocaine among men taking amantadine at the
2-week and 1-month follow-up visits.
120Amantadine 100
mg administered three times daily,however,was no more
effective than placebo in reducing cocaine use.
122
Amantadine also effectively reduced cocaine use among
subjects with severe cocaine withdrawal symptoms at the
start of treatment.
123Though results of clinical trials do
not appear to support amantadine as a treatment for
cocaine dependence, further controlled studies are
needed to determine if amantadine is efficacious in
cocaine users with high withdrawal severity.
Modafinil,a medication used to treat narcolepsy,is a gen-
erally well-tolerated with low abuse potential,therefore
it is frequently used for off-label indications such as
attention deficit hyperactivity disorder (ADHD),depres-
sion,and cocaine dependence and withdrawal.
124,125The
mechanism of action blunts cocaine euphoria under con-
trolled conditions, acting as a glutamate-enhancing
agent.
124,126 Reduction in impulse responding has been
seen among healthy volunteers as well as in patients with
ADHD.
127,128 In the first double-blind,placebo-controlled
trial in 62 cocaine-dependent patients,modafinil reduced
cocaine use to a greater extent than placebo.Modafinil
patients provided significantly more cocaine–free urine
samples compared with placebos,and were more likely
to achieve a protracted period of cocaine abstinence.
126
Cocaine vaccine 
Studies evaluating the efficacy of vaccination in cocaine
addicts have shown reduction in some cocaine effects.A
cocaine vaccine evaluated in clinical trials has used
cholera toxin B subunit as a carrier protein linked to nor-
cocaine at the methyl ester group as an immunogen.
129 In
phase I and early phase II trials of immunogenicity,
safety,and efficacy,no serious adverse effects had been
found and the vaccine showed a reduction in cocaine
effects during human laboratory cocaine administration
studies and cocaine use in outpatient studies.
129-132 In a
Phase I safety and immunogenicity trial, the vaccine
induced cocaine-specific IgG cocaine antibodies, both
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with no serious adverse effects during 12 months of fol-
low-up.
129 In a Phase IIa, 14-week trial of 18 cocaine-
dependent subjects in early recovery,conjugated cocaine
vaccine was well tolerated at two dose levels (400 µg and
2000 µg). Cocaine-specific antibodies persisted for at
least 6 months.
130 Furthermore,subjects who received the
higher dose of vaccine had significantly higher mean anti-
body titer response and were more likely to maintain
cocaine-free urines than the lower-dose group.
131 Results
demonstrated that a cocaine-specific vaccine can elicit
a sufficient immunologic response that reduces cocaine
usage and attenuates the self-reported psychological
effects of cocaine during use.Since it is possible to over-
ride the effects by the vaccine by increasing the amount
of cocaine usage, the vaccine is primarily for use in
cocaine users who are motivated to quit.
Opiates
Chronic illicit opiate use affects over 900 000 people in the
US and an estimated 13 million people abused opiate
drugs worldwide in 1999-2001, according to the World
Health Organization.
133 More recently,prescription opiate
abuse has become widespread with an estimated 4 million
additional opiate abusers.
2 Opiate dependence is a chronic
and relapsing medical disorder with a well-documented
neurobiological basis,and that necessitates the use of long-
term pharmacologic and behavioral intervention.
Following acute withdrawal,individuals can be maintained
on methadone,buprenorphine,or naltrexone.Although
these highly effective pharmacotherapies for opioid
dependence are available,only about 20% of illicit opioid
users are enrolled in treatment programs.
134 Until recently,
licensed opiate treatment facilities were the only providers
of opioid maintenance therapy using methadone.Recent
legislation changes and availability of sublingual Suboxone
(buprenorphine plus naloxone) now enable general prac-
titioners to offer opiate agonist treatment to as many as
100 patients through their offices.
135
Opioid agonists
Methadone is a µ-opioid agonist that directly stimulates
the opiate receptor and acts as a replacement to the
abused drug.Through development of cross-tolerance at
doses of 100 mg or more per day, methadone blocks
heroin effects as well as other opioids.
136 Morphine-like
effects evident in humans and include euphoria,drowsi-
ness,analgesia,and nausea.Since its introduction in the
1960s it has been the gold standard for opioid mainte-
nance treatment.
137 Initial clinical trials testing methadone
for efficacy in the treatment of opioid dependence have
found it to be safe and effective,
138-140 particularly if com-
bined with monitoring and behavioral interventions.
Daily doses administered in methadone maintenance
programs range from 30 to 100 mg,typically starting at
lower levels (15 to 20 mg/day) with subsequent daily
increases based on the patient tolerance.
140 Outpatient
studies examining higher versus lower doses of
methadone indicate greater reduction in opioid use with
higher doses of methadone.
141,142 Furthermore,doses over
100 mg/day may be indicated in patients with persistent
heroin abuse or with comorbid conditions such as HIV
infection,since some concomitant medications for AIDS
increase metabolism of methadone.
143,144Tapering doses
of methadone can be used in ambulatory detoxification,
but the protracted withdrawal syndrome associated with
methadone cessation contributes to a high rate of recidi-
vism to opiate abuse.
145,146 Methadone is therefore most
often used in maintenance therapy and not for acute
withdrawal or detoxification.
Partial agonists act like agonists,but do not stimulate the
receptor to the same degree.In combining both a block-
ing and substitution approach,buprenorphine,a partial
agonist at the µ-opioid receptor,suppresses withdrawal
symptoms and produces some subjective reinforcing
properties at low doses.Initial clinical trials of buprenor-
phine demonstrated efficacy in the outpatient setting.At
8 mg,the sublingual buprenorphine (in liquid formula-
tion) treatment group demonstrated better study reten-
tion and decreased opiate use than active placebo or 1mg
buprenorphine.
147,148At higher doses buprenorphine acts
as an antagonist,and blocks the reinforcing properties of
the agonist,resulting in lowered risk of abuse liability and
potential for abuse of the drug.
149 Buprenorphine is avail-
able alone or in a 4:1 combination sublingual tablet with
naloxone (Suboxone).
150 A multicenter, randomized,
placebo-controlled clinical trial comparing buprenor-
phine tablet, Suboxone tablet, and placebo in opiate-
dependent patients found that both buprenorphine alone
and Suboxone reduced opiate use in the first month of
the study compared with placebo.
151 Suboxone also
appears to decrease the potential for abuse or diversion
compared with methadone.
152 Injection of Suboxone
could also precipitate opioid withdrawal.
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Table I. Pharmacotherapeutic options for substances of abuse.
Drug Medication Dose Mechanism of action Special considerations References
Nicotine Transdermal patch* 11-22 mg Nicotine replacement therapy  Available over-the-counter  5,8-12
16- or 24-h delivery (NRT) (OTC)
6- to 12-week 
duration w/ taper
Polacrilex gum* 2 or 4 mg NRT OTC 6,8,14
1 pc/1-2 h Avoid acidic beverages
6- to 12-week
duration w/ taper
Lozenge* 2 or 4 mg NRT OTC 6,8,13
6 to 12 week  Do not chew, avoid acidic beverages
duration w/ taper
Inhaler* 1 mg/admin NRT Rapid delivery of nicotine, therefore 20,21
Each nostril Q 1-2 h some potential for abuse liability
8-40 doses/day
8 weeks w/ taper wks 9-14
Nasal spray* 0.013 mg nicotine/ NRT Rapid delivery of nicotine, therefore 25,26
puff 10 mg nicotine/ some potential for abuse liability
cartridge for 20 min of puffing
6-16 cartridges/day
12 weeks
Bupropion* 150 mg/day (7 d prior to  Antidepressant 2nd line: recommended to start 21,37
quit date) prior to quit date; can be used
300 mg/day after 3-4 days in conjunction with NRT
Nortryptylene 25 mg TID-QID Antidepressant 2nd line; toxicity in overdose amounts 39,40
Clonidine 0.1–0.3 mg/24-h ES patch Antihypertensive 2nd line 41-43
0.1-1.3 mg tablet
Selegiline 5 mg BID cap Antihypertensive; 2nd line 44-45
6-12 mg/24-h patch MAO-B inhibitor
Varenicline* Titrate: 0.5 mg daily  Partial agonist 46
to 1 mg BID
NicVAX ** Nicotine vaccine Phase II clinical trials 48
CYT002-NicOb ** Nicotine vaccine Phase IIb/III trial planned 49,51
TA-NIC ** Nicotine vaccine Phase II 50
Alcohol Chlordiazepoxide* 50-100 mg IM/IV  Benzodiazepine Acute withdrawal 54-55
(may repeat in 2-4 h)
Clonazepam* 0.25 mg bid Benzodiazepine Acute withdrawal 54-55
(max 4 mg/day)
Diazepam* 10 mg IM/IV, then  Benzodiazepine Acute withdrawal 54-55
5-10 mg in 3-4 h prn
Oxazepam* 15-30 mg TID-QID Benzodiazepine Acute withdrawal 54-55
Lorazepam* 0.05 mg/kg IM Benzodiazepine Acute withdrawal 54-55
2 mg or 0.044 mg/kg 
IV2-3 mg BID tabTherapeutic options and challenges - Gardner and Kosten Dialogues in Clinical Neuroscience - Vol 9 . No.4 . 2007
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Table I. continued
Drug Medication Dose Mechanism of action Special considerations References
Carbamazepine 200 mg BID Anticonvulsant; antiepileptic Acute withdrawal, widely used 56-59
(Max 1200 mg/day)
Valproate 15 mgkg/day Anticonvulsant Acute withdrawal 6
(Max. 60 mg/kg/day)
Disulfiram* 250 mg/day Alcohol-sensitizing agent Relapse prevention and  60,61
(125 to 500 mg/day) - inhibits enzymatic conversion  maintenance; subject should be 
of acetylaldehyde to acetic acid motivated to quit
Naltrexone* 50 mg oral admin Opioid receptor antagonist Relapse prevention and 68-70
12 weeks maintenance; mediates rewarding
Extended release Q 4 wks effects of alcohol
Acamprosate* 2 g/3 x day Normalizes the dysregulation Relapse prevention 76,77
(usual dose: 666 mg TID) of NMDA-mediated  and maintenance
glutaminergic excitation
Topiramate 25 mg BID Antiepileptic; Relapse prevention 78
(titrate weekly to 400 mg/day)  GABA agonist and maintenance
Buspirone 7.5 mg BID Serotonin (5-HT)-1A Relapse prevention 80
(titrate to 20-30 mg/day) agonist and maintenance
Fluoxetine 6-25 mg/day Selective serotonin Relapse prevention 82,85,87
90 mg/week uptake inhibitor (SSRI) and maintenance
Citalopram 20 – 40 mg/day SSRI Relapse prevention  83,84,86,88
and maintenance
Ondansetron 2 mg/mL, 32 mg/50 mL  5-HT3 antagonist; Relapse prevention 81
injection prevention of nausea/vomiting and maintenance
4 mg/5 mL solution
4 – 24 mg tab
Cocaine Disulfiram (Antabuse) 250 mg/day Nonspecific enzyme inhibitor  Good efficacy data 92,93
including aldehyde dehydrogenase  in nonalcoholics,
and dopamine beta hydroxylase relatively contraindicated in 
alcohol dependence with cocaine
Selegiline 5 mg BID cap Antihypertensive; 97-99
6-12 mg/24 h patch MAO-B inhibitor
Desipiramine 100-200 mg/day Antidepressant 6,100,101
(max 300 mg/day)
Baclofen 40-80 mg/day GABA agonist Additive CNS effects w/ alcohol 109
Tiagabine 4 mg/day (may increase  Anti-seizure; Additive CNS depression 110,111
to max 56 mg/day) GABA agonist w/ alcohol
Topiramate 25 mg bid Antiepileptic/antiseizure; Potentiates CNS depression 112
(titrate weekly to  GABA agonist w/ alcohol; withdraw gradually
400 mg/day)
Vigabatrin ** GABA agonist 113
Carbamazepine 200 mg BID Anticonvulsant; Inconsistent results from clinical trials 114,115
(Max 1200 mg/day Antiepileptic
Buprenorphine 8 mg sublingual (liquid) Partial agonist at Inconsistent results from  116,119
1 mg tablet mu-opioid receptor clinical trials; low abuse
4:1 combination sublingual   potential
tablet w/ naloxone (Suboxone)Opioid antagonists
Naltrexone is an opioid antagonist that binds to recep-
tors, but instead of activating the receptors, it blocks
them,effectively removing the opiate user’s ability to get
high.
153,154 Human laboratory studies of naltrexone have
demonstrated the efficacy of naltrexone in blocking the
effects of acute opioid use in human volunteers who have
been withdrawn from opioids.
154,155 In clinical trials,high
attrition rates and unblinding by study patients who
guess their treatment regimen have limited the utility of
naltrexone maintenance treatment trials,
156,157 though a
subgroup analysis in a large controlled trial indicated
potential efficacy in highly motivated patients and in
those already in drug-free counseling.
157 Naltrexone has
relatively few side effects, but liver function should be
monitored as per labeling guidelines.Its depot formula-
tion is particularly useful to address its main problem of
poor adherence to the daily oral therapy,but the relative
expense of depot compared with oral naltrexone can be
a deterrent to potential widespread utilization.Patients
must also be opiate free for 7 to 10 days prior to initia-
tion in order to prevent severe withdrawal reactions.If
naltrexone is intended for use as treatment of acute with-
drawal symptoms,use of clonidine in combination with
naltrexone reduces the severity of acute opioid with-
drawal during detoxification.
Behavioral therapy
Behavioral therapies constitute an extremely important
component of substance abuse treatment by helping to
retain patients in treatment and improvement in absti-
nence.
158These therapies form the platform for any phar-
macotherapy in order to engage the patient and facilitate
more long-term changes including prevention of
relapse.
159,160 Contingency management (CM) deserves
special mention because it has been successful to initiate
abstinence and prevent relapse with many drugs of
abuse,particularly for managing cocaine- and ampheta-
mine-abusing individuals,
161-165 regardless of psychiatric
severity.
166 Improvement in study retention, as well as
associated abstinence outcomes in substance abusers,has
been found in randomized clinical trials of cocaine
users
163,166 and in cocaine and methadone-maintained
cocaine abusers.
163 CM has also been successful in stud-
ies of alcohol-abusing subjects,as well as those with poly-





Drug Medication Dose Mechanism of action Special considerations References
Amantadine 200 mg/day Dopamine & NMDA agonist Inconsistent results from  120-123
clinical trials; potential use in 
severe withdrawal
Modafinil 200 mg/day Wakefulness-promoting agent Low abuse potential;  124,125
often used for many 
off-label indications
TA-CD ** Cocaine vaccine Phase II trials; must be 129-131
motivated to quit
Opiates Methadone* 30 – 100 mg/daily  mu-opioid Gold standard for 136-144
(initial doses 15 to 20 mg/day) agonist opioid maintenance treatment
>100 mg/day in persistent 
heroin abuse or comorbid 
conditions
Buprenorphine* 8 mg sublingual (liquid) Partial agonist at Injection of suboxone could 147-152
1 mg tablet mu-opioid receptor & precipitate opiate withdrawal
4:1 combination sublingual kappa antagonist
tablet w/ naloxone (Suboxone)
Naltrexone 50 mg oral admin* Nonspecific opioid  Few side effects but monitor 154-157
Depot: extended release antagonist  liver function; must be 
opiate free for 7 to 10 days 
prior to initiationefforts using CM have also been successful in improving
retention and associated abstinence outcomes.
165There is
however,a significantly higher cost associated with the
incentives group versus usual care group,
168 and therefore
the utility of CM in real-world settings should be further
evaluated based on cost-effectiveness.
Cognitive behavior therapy (CBT) is also an efficacious
intervention for the treatment of substance abuse.In a
pilot study CBT was examined in conjunction with phar-
macotherapy to evaluate length of treatment,drug-free
urinalyses,and reduction of alcohol and cocaine craving.
Though CBT-treated subjects remained in treatment
longer than subjects who received both disulfiram/CBT
or naltrexone/CBT,the combination treatment groups
achieved significantly greater reductions in cocaine pos-
itive urinalyses.
169Where CM may be useful in engaging
substance users and attaining abstinence more quickly,
CBT has better long-term treatment retention and is




Substantial progress has been made in the development of
pharmacotherapeutic options for substance use disorders.
Table I summarizes the current therapeutic options for the
substances of abuse mentioned in this review.Taken alone,
in combination with other medications,or in conjunction
with behavioral therapies,effective treatment options are
available in the areas of nicotine,alcohol,cocaine,and opi-
oid abuse. Preliminary studies on new medications and
vaccines are promising for the future. ❏
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